Omstapocus
$MDXG I think the best way to look at MDXG is the following :
FTC second request not death kneel.Approval is more the norm ie Speed bump.Sanara third quarter revenue PLUS MDXG forcast $375M+ year end revenue,significant cash in the bank and consistent 20% EBITHA!
No indication CMS will increase reimbursement so ?? there will be growth in that area.
Conversion to “surgical company“ great BUT no articulation regarding product pipeline for clinical problems .Sanara does addresses specific products like bone and infection control that address surgical.
With lack of any pipeline plan ,future mature stand alone surgical company doubtful M&A most likely.Sooner than later seems most likely.
It would seem more robust and targeted clinical opportunities amenable to dHACM prophylaxis and repair would make M&A more attractive and to shareholder $$$ benefit.
My guess Sanara acquisition … For Sale Sign.
We actually may get out of this nightmare!
4

:format(webp)/https%3A%2F%2Fst-everywhere-cms-prod.s3.us-east-1.amazonaws.com%2Flarge_Getty_Images_2278962574_aa49bd3b68.jpg)